Trials / Recruiting
RecruitingNCT06976268
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 550 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-8000 | BHV-8000 10 mg. Participants will take blinded investigational product (IP) once daily |
| DRUG | BHV-8000 | BHV-8000 20 mg. Participants will take blinded investigational product (IP) once daily |
| DRUG | Placebo | Matching placebo taken once daily |
Timeline
- Start date
- 2025-05-28
- Primary completion
- 2027-08-01
- Completion
- 2027-09-01
- First posted
- 2025-05-16
- Last updated
- 2026-01-14
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06976268. Inclusion in this directory is not an endorsement.